At PROMETRIKA, we continuously evaluate how emerging technologies can strengthen clinical trial execution, compliance, and data integrity. As trials become more complex and adaptive, systems like Interactive Response Technologies (IRT) - also known as Randomization and Trial Supply Management (RTSM) – need to adapt accordingly to keep up with the increased demands of these trial designs.
The recent IRT Conference in Boston, MA brought together industry leaders to discuss the evolution of IRT, its expanding role in personalized medicine, and the role that artificial intelligence (AI) can play. The conversations reflected both how far the industry has come and how much remains to be defined as the landscape of clinical trials continues to advance. Members of PROMETRIKA’s Clinical Innovations Core attended to hear about the latest trends in IRT.
Balancing Innovation with Simplicity
Ten years ago, sealed envelopes containing randomization codes were still commonplace for patient randomization. Today, IRT systems are ubiquitous across global clinical trials, coordinating shipments, randomizations, and inventory across sites and depots. But with innovation comes complexity.
Clinical research coordinators and site teams must learn and adapt to new digital workflows, while sponsors and drug depots depend on IRT to manage intricate IP logistics. Speakers at the conference emphasized that as systems become more powerful, they must also remain as simple as possible to reduce risk. The core function of the IRT must be preserved without trying to overcomplicate the system with unnecessary requirements that are better handled within other applications.
For example, there were discussions around whether the IRT should capture dose calculations. Most of the audience agreed that the IRT should not capture the dose calculation, and that it should be captured in the electronic data capture (EDC) system. However, it was noted that in these circumstances, if the EDC and IRT are not integrated, an additional reconciliation step is required between the dose calculation and what was actually dispensed - highlighting the ongoing tension between system functionality and operational simplicity.
Supporting the Future of Personalized Medicine
IRT is also playing an integral role in personalized and precision medicine clinical trials. As genotyping and biomarker-driven trials become more common, IRT enables real-time manufacturing and distribution of IP, personalized to the attributes of each study participant.
Coordinating the right dose for the right patient at the right time demands a high level of automation and traceability - something only IRT can deliver. In this environment, IRT has evolved from a logistical tool to a critical operational backbone that supports both patient safety and data integrity.
The Role of AI: Assistive, Not Autonomous
Discussions of AI dominated many of the sessions, with broad interest - and healthy skepticism - about its readiness in IRT design and implementation.
Potential applications for AI in IRT include:
- Interpreting protocols to generate User Requirements Specifications (URS)
- Drafting test scripts or validation plans
- Conducting repetitive quality checks to identify audit trail anomalies or suspicious transactions
- Detecting unblinded user access patterns or non-ALCOA-compliant documentation
Attendees generally agreed that given the high-risk nature of IRTs, using AI to draft the URS and test script or validation plans is purely aspirational at this point in time. However, AI’s potential to enhance signal detection, risk monitoring, and data oversight is clear. Even so, operationalizing it still requires well-defined governance. Sponsors and vendors will need to establish dedicated AI SOPs to specify how these tools are trained, validated, and audited.
Looking Ahead
From paper envelopes to real-time supply automation, IRT’s journey reflects the broader digital transformation of clinical research. The goal, however, remains the same: to ensure accuracy, compliance, and patient safety through every phase of a clinical trial.
At PROMETRIKA, we remain committed to advancing this mission - leveraging innovation responsibly, balancing simplicity with sophistication, and empowering our partners to deliver high-quality, compliant results in an evolving clinical landscape.
